Drug Development
AstraZeneca’s $15 billion pledge to its China operations highlights the country’s advantages. But other regions are also hoping to host more clinical studies.
FEATURED STORIES
Together with robust data-driven modeling, rethinking regulation and data use could push forward a notoriously challenging field.
From opening new therapeutic mechanisms to repairing neuronal damage, investigational molecules from Ventyx Therapeutics, AC Immune, Gain Therapeutics and more could shape the future of Parkinson’s disease treatment.
As drug candidates discovered via AI move into later-stage clinical trials, the technology seems to be doing as promised: speeding drug development.
Subscribe to ClinicaSpace
Clinical trial results, research news, the latest in cancer and cell and gene therapy, in your inbox every Monday
THE LATEST
Moderna will construct a manufacturing facility in Canada to provide direct access to mRNA vaccines for the COVID-19 pandemic and future viral threats and respiratory viruses.
On Monday, BioNTech announced revenues of €5.308 billion (about $6.2 billion) for the quarter.
As the Delta variant rages on and COVID-19 vaccines move closer to receiving full regulatory approval, many companies across the U.S. and abroad are beginning to mandate their employees get the jab or get the boot.
Months after landing a massive SPAC deal that carried Ginkgo Bioworks to the Nasdaq, the company is now touting a manufacturing breakthrough from partner Aldevron for mRNA vaccine components.
Global biopharmaceutical firms Santen SA and Sydnexis have entered an exclusive licensing deal for a drug formulation that aims to treat progressive myopia.
In India, only 8.3% of the population is fully vaccinated, while Sudan, Myanmar, and Ethiopia all have blank spaces beside their names in that category.
New therapeutic modalities always face an uphill climb, but the urgency of COVID-19 may have opened the door for two related ones: cell therapies and exosomes.
The hold is related to a report of a SUSAR of myelodysplastic syndrome in a patient treated with eli-cel, also known as Lenti-D, in a Phase III clinical trial.
Sanofi has announced that the U.S. FDA approved its new treatment for children one year of age or older diagnosed with late-onset Pompe disease.
Called “female Viagra” in the media, Ovoca Bio’s BP-101 (Libicore) nasal spray therapy for low libidos in premenopausal women is undergoing Phase II trials.